Pfizer’s Albert Bourla and Hiroshi Matsumori on Established Brands In Japan: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Last week’s exclusive partnership with Mylan has put Pfizer in a much stronger position in Japan’s generics market. The question remains whether it can navigate Japan’s unique Gx challenges.
You may also be interested in...
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.